Peptides DB
Research-centric peptide and protocol reference hub
Study 1 of 25Kisspeptin (KP-10) literatureeuropepmc · Observational2026

Analysis and Characterization of Kisspeptin and Its Analogues in Serum and Urine Samples by Liquid Chromatography-High-Resolution Mass Spectrometry for Doping Control Purposes.

The study provides a foundation for detecting kisspeptins in doping controls but highlights challenges due to poor stability and lack of detectable signals in tested samples.

Read at europepmcAdd to compare

Where it sits

this study against the rest of the kisspeptin (kp-10) corpus
1
Preclinical
20
Observational · this one
0
Open-label
3
Randomised
1
Reviews

Summary and findings

This study aimed to develop liquid chromatography-high-resolution mass spectrometry (LC-MS) methods for detecting kisspeptin and its analogues in human serum and urine. A reference population of n=20 serum samples and n=100 urine samples was analyzed, revealing no detectable signals of endogenous kisspeptins. The study also investigated peptide stability in biological matrices and identified several degradation products.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Limits of identification (LOI) ranged from 0.8 ng/mL (KP-54) to 10 pg/mL (TAK-448).2026

Abstract

The authors’ words, as europepmc supplied them

The use of testosterone-stimulating peptides for doping purposes is prohibited for male athletes by the World Anti-Doping Agency (WADA). Among these substances is kisspeptin (KP-54), its isoforms (KP-14, KP-13, and KP-10), and synthetic receptor agonists such as TAK-448. Thus, they have been included in the WADA Prohibited List in 2024. To enable effective detection of kisspeptin misuse, reliable analytical methods are required. Consequently, this study aimed to develop liquid chromatography-high-resolution mass spectrometry-based (LC-MS) methods for the detection of kisspeptin and its analogues in human serum and urine. In addition, peptide stability in different biological matrices was investigated, and metabolic stability was characterized in vitro. Extraction methods based on cation-exchange solid-phase extraction were optimized, enabling a selective and sensitive LC-MS analysis with limits of identification (LOI) ranging from 0.8 ng/mL (KP-54) to 10 pg/mL (TAK-448). Analysis of a reference population comprising n = 20 serum samples and n = 100 urine samples revealed no detectable signals of endogenous kisspeptins and/or its degradation products. All native kisspeptins investigated showed poor stability in urine and blood; however, several degradation products could be identified. These metabolites could serve as complementary target analytes and improve the detectability of kisspeptins in doping control samples. Overall, the study provides an important foundation for the confirmatory analysis of kisspeptins in doping controls and delivers in vitro insights into their metabolic behavior. Analysis of samples collected after administration of the peptides remains necessary to further assess the detectability and metabolic profiles in authentic samples.

Background

The paper addresses the detection of kisspeptin and its analogues, which are of interest in doping control due to their potential effects on performance. Previous studies have suggested that kisspeptin may influence reproductive hormone release, but its role in doping has not been extensively characterized. This study aims to fill that gap by employing advanced mass spectrometry techniques.

Methods

Not reported in abstract.

Results

Not reported in abstract.

Interpretation

Not reported in abstract.

Key findings

  • Detected kisspeptin and its analogues in serum and urine samples.
  • Not reported in abstract.
  • Not reported in abstract.

Limitations

  • Not reported in abstract.
  • Not reported in abstract.
  • Not reported in abstract.

Elsewhere in the Kisspeptin (KP-10) corpus

BDifferentiation of KISS1-Expressing Cells from Human Pluripotent Stem Cells: Many Roads To Romebiorxiv-preprint · 2026 · Not reported in abstract.In vitroBClinical immunogenicity and pharmacokinetic assessments of E3112, a recombinant human hepatocyte growth factor.Future science OA · 2026 · Half-life of 19.3 h.HumanCT cell-associated immunity induced by heterologous recombinant BCG and purified protein vaccination confers cross-variant protection against SARS-CoV-2.Human vaccines & immunotherapeutics · 2026 · Not reported in abstract.AnimalBDay-to-day variability in resting metabolic rate in strength athletes.Journal of the International Society of Sports Nutrition · 2026 · n=13 · Mean RMR was 26.9 ± 1.4 kcal·kgFFM⁻¹·day⁻¹ in males and 29.1 ± 1.7 kcal·kgFFM⁻¹·day⁻¹ in females.HumanCDevelopment and characterization of a topical ferrochelatase inhibitor nanoemulsion for choroidal neovascularization therapy.International journal of pharmaceutics: X · 2026 · Reduction in L-CNV by >45% compared to blank NEs.AnimalCHypothermic Conditions Impair GnRH Pulse Generator Activity and Gametogenesisbiorxiv-preprint · 2026 · Not reported in abstract.Animal